Temperature-triggered tumor-specific delivery of anticancer agents by cRGD-conjugated thermosensitive liposomes.
One of the most effective methods to treat cancer is the specific delivery of anticancer drugs to the target site. To achieve this goal, we designed an anticancer drug with mild hyperthermia-mediated triggering and tumor-specific delivery. To enhance the thermosensitive drug release, we incorporated elastin-like polypeptide (ELP), which is known to be a thermally responsive phase transition peptide into the dipalmitoylphosphatidylcholine (DPPC)-based liposome surface. Additionally, cyclic arginine-glycine-aspartic acid (cRGD) binds to αvβ3 integrin, which is overexpressed in angiogenic vasculature and tumor cells, was introduced on the liposome. ELP-modified liposomes with the cRGD targeting moiety were prepared using a lipid film hydration method, and doxorubicin (DOX) was loaded into the liposome by the ammonium sulfate-gradient method. The cRGD-targeted and ELP-modified DOX-encapsulated liposomes (RELs) formed spherical vesicles with a mean diameter of 181 nm. The RELs showed 75% and 83% DOX release at 42°C and 45°C, respectively. The stability of RELs was maintained up to 12h without the loss of their thermosensitive function for drug release. Flow cytometry results showed that the cellular uptake of DOX in RELs into αvβ3 integrin-overexpressing U87MG and HUVEC cells was 8-fold and 10-fold higher, respectively, than that of non-targeting liposomes. Confocal microscopy revealed that REL released DOX only under the mild hyperthermia condition at 42°C by showing the localization of DOX in nuclei and the liposomes in the cytosol. The cell cytotoxicity results demonstrated that REL can efficiently kill U87MG cells through cRGD targeting and thermal triggering. The in vivo tumoral accumulation measurement showed that the tumor-targeting effect of RELs was 5-fold higher than that of non-targeting liposomes. This stable, target-specific, and thermosensitive liposome shows promise to enhance therapeutic efficacy if it is applied along with a relevant external heat-generating medical system.
Drug Delivery System Group, Bio Research Center, Samsung Advanced Institute of Technology (SAIT), Samsung Electronics Co., Ltd., Yongin 446-712, South Korea.
Min Sang
MS
Kim
Drug Delivery System Group, Bio Research Center, Samsung Advanced Institute of Technology (SAIT), Samsung Electronics Co., Ltd., Yongin 446-712, South Korea.
Don-Wook
DW
Lee
Drug Delivery System Group, Bio Research Center, Samsung Advanced Institute of Technology (SAIT), Samsung Electronics Co., Ltd., Yongin 446-712, South Korea.
Kitae
K
Park
Drug Delivery System Group, Bio Research Center, Samsung Advanced Institute of Technology (SAIT), Samsung Electronics Co., Ltd., Yongin 446-712, South Korea.
Sang-Jun
SJ
Park
Drug Delivery System Group, Bio Research Center, Samsung Advanced Institute of Technology (SAIT), Samsung Electronics Co., Ltd., Yongin 446-712, South Korea.
Eun-Jung
EJ
Choi
Drug Delivery System Group, Bio Research Center, Samsung Advanced Institute of Technology (SAIT), Samsung Electronics Co., Ltd., Yongin 446-712, South Korea.
Eun Sung
ES
Park
Drug Delivery System Group, Bio Research Center, Samsung Advanced Institute of Technology (SAIT), Samsung Electronics Co., Ltd., Yongin 446-712, South Korea. Electronic address: hyunryoung@hotmail.com.
Hyun Ryoung
HR
Kim
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology; D016503:Drug Delivery Systems / Q000379:methods*; D061307:Human Umbilical Vein Endothelial Cells / Q000378:metabolism; D006801:Humans; D008081:Liposomes; D015394:Molecular Structure; D010456:Peptides, Cyclic / Q000008:administration & dosage* / Q000737:chemistry*; D013329:Structure-Activity Relationship; D013379:Substrate Specificity; D013696:Temperature
D000970:Antineoplastic Agents; D008081:Liposomes; D010456:Peptides, Cyclic; C507169:cyclic arginine-glycine-aspartic acid peptide; D004317:Doxorubicin
Drug delivery; Liposome; RGD conjugation; Temperature sensitive